Detection of Circulating Tumor DNA in Patients With Leiomyosarcoma With Progressive Disease
Authors:
- Matthew L. HemmingMHMatthew L. Hemming
- Kelly KlegaKKKelly Klega
- Justin RhoadesJRJustin Rhoades
- Gavin HaGHGavin Ha
- Kate E. AckerKAKate E. Acker
- Jessica L. AndersenJAJessica L. Andersen
- Edwin ThaiETEdwin Thai
- Anwesha NagANAnwesha Nag
- Aaron R. ThornerATAaron R. Thorner
- Chandrajit P. RautCRChandrajit P. Raut
- Suzanne GeorgeSGSuzanne George
- Brian D. CromptonBCBrian D. Crompton
- 1 December 2019
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 3 (3) , 1-11
Abstract
Purpose: Leiomyosarcoma (LMS) is a soft-tissue sarcoma characterized by multiple copy number alterations (CNAs) and without common recurrent single-nucleotide variants. We evaluated the feasibility of detecting circulating tumor DNA (ctDNA) with next-generation sequencing in a cohort of patients with LMS whose tumor burden ranged from no evidence of disease to metastatic progressive disease. Patients and Methods: We evaluated cell-free DNA in plasma samples and paired genomic DNA from resected tumors from patients with LMS by ultra-low passage whole-genome sequencing. Sequencing reads were aligned to the human genome and CNAs that were identified in cell-free DNA and tumor DNA by ichorCNA software to determine the presence of ctDNA. Clinical data were reviewed to assess disease burden and clinicopathologic features. Results: We identified LMS ctDNA in 11 (69%) of 16 patients with disease progression and total tumor burden greater than 5 cm. Sixteen patients with stable disease or low disease burden at the time of blood draw were found to have no detectable ctDNA. Higher ctDNA fraction of total cell-free DNA was associated with increasing tumor size and disease progression. Conserved CNAs were found between primary tumors and ctDNA in each case, and recurrent CNAs were found across LMS samples. ctDNA levels declined after resection of progressive disease in one case and became detectable upon disease relapse in another individual patient. Conclusion: These results suggest that ctDNA, assayed by a widely available sequencing approach, may be useful as a biomarker for a subset of patients with uterine and extrauterine LMS. Higher levels of ctDNA correlate with tumor size and disease progression. Liquid biopsies may assist in guiding treatment decisions, monitoring response to systemic therapy, surveying for disease recurrence, and differentiating benign and malignant smooth muscle tumors.Keywords
This publication has 35 references indexed in Scilit:
- Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome SequencingScience Translational Medicine, 2012
- Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular TestingPLOS ONE, 2011
- GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancersGenome Biology, 2011
- A framework for variation discovery and genotyping using next-generation DNA sequencing dataNature Genetics, 2011
- The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing dataGenome Research, 2010
- Fast and accurate short read alignment with Burrows–Wheeler transformBioinformatics, 2009
- Strong Smooth Muscle Differentiation Is Dependent on Myocardin Gene Amplification in Most Human Retroperitoneal LeiomyosarcomasCancer Research, 2009
- Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)European Journal of Cancer, 2008
- Radiation-induced sarcoma: 25-year experience from The Norwegian Radium HospitalActa Oncologica, 2008
- Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 casesInternational Journal of Cancer, 2006